Glutathione injections: prices, evidence & 2026 recall

The exact scope of the August 2026 recall

The announcement covers Optimal Balance Pharmacy's compounded glutathione injection, 200 mg/mL in a 30 mL multidose vial, lot LG342009076, with an expiration date of 4 October 2026. Optimal Balance said pharmacy testing found elevated bacterial endotoxin and initiated a patient-level recall. The company announcement date was 19 August; FDA posted it on 20 August 2026.

The notice lists distribution to Arizona, Colorado, Florida, Illinois, Louisiana, Michigan, New York, Nevada, Oklahoma, Pennsylvania, Texas, Utah, Vermont, and Washington. It does not identify every glutathione injection as recalled. We also found no evidence in the sources reviewed connecting a provider in this directory to Optimal Balance Pharmacy or the recalled lot.

People holding the identified product should follow the notice rather than a summary: stop using it, quarantine it, contact Optimal Balance Pharmacy to arrange retrieval, and contact the prescribing clinician if symptoms or problems may be related. The announcement says the pharmacy is arranging refunds for recalled product and gives instructions for reporting adverse events through FDA MedWatch.

How published telehealth prices compare

We found several current provider structures. Some publish continuing prices that can sit in the same ranked comparison. Others use a separate membership, a starting price, or a package whose refill cadence differs. Those figures remain visible, but we label them separately instead of pretending every dollar amount buys the same thing.

“Monthly” is not a complete unit of comparison by itself. The useful denominator is the full recurring cost for a defined quantity and refill interval, including any required care membership. A lower headline can become a higher effective cost when medication, supplies, shipping, or follow-up is billed separately.

These are published program figures, not a guarantee of eligibility, prescribing, total checkout cost, or medication availability.

Why the endotoxin finding matters

The recall is a product-quality event, not a conclusion about whether glutathione works for a particular claim. The company's risk statement says injectable products with elevated endotoxin levels can cause fever, low blood pressure, inflammatory reactions, anaphylactic shock, and death. Reported adverse events included fever, chills, severe headache, nausea, vomiting, pain, and symptoms consistent with an allergic reaction.

FDA had raised a separate glutathione compounding concern in 2019 after patients experienced reactions to injections compounded with an ingredient labeled for dietary-supplement use. FDA testing found excessive bacterial endotoxin in the sampled material. That earlier event is not the same lot or pharmacy as the 2026 recall, but it explains why ingredient grade, sterile-production controls, and lot-level traceability are material questions for an injectable product.

FDA's 2019 alert emphasized that testing alone should not substitute for building quality into production. For a consumer comparing telehealth programs, the practical question is therefore not only “what does it cost?” but also “which pharmacy makes it, what product will I receive, and how will a recall reach me?”

What a published price does not prove

A price page can document the commercial terms a provider chose to publish. It cannot establish that a clinician will prescribe, that the medication is appropriate for a particular person, or that a pharmacy has stock. Before treating two prices as comparable, confirm the same five fields:

• The medication quantity and concentration covered by the price.
• Whether clinician visits, follow-up, supplies, and shipping are included.
• The refill interval and whether the displayed amount is introductory or ongoing.
• Any required membership, laboratory work, or cancellation charge.
• The dispensing pharmacy and the states in which the program is available.

Telehealth Ledger ranks only structures that are comparable from the published evidence. A separately labeled listing is not necessarily worse; it means the terms are different or incomplete enough that ranking it beside a medication-inclusive monthly plan would be misleading.

What the clinical evidence can—and cannot—support

Glutathione is a naturally occurring tripeptide involved in intracellular redox balance. That biological role does not establish that an injected product is effective for every “detox,” immune, wellness, anti-aging, or cosmetic claim attached to it. Route, dose, formulation, indication, and study design all matter.

A systematic review published online in 2024 and in a 2025 journal issue examined glutathione for skin lightening and melasma. It found multiple small studies of oral or topical formulations, but only one placebo-controlled intravenous study. In that IV study, the reported difference did not reach conventional statistical significance. The review characterized intravenous use for skin lightening as unsupported because of limited efficacy evidence and adverse effects.

A 2016 review reached a similar route-specific conclusion: it described topical and oral trials but found no evidence proving the efficacy of intravenous glutathione for skin lightening. The difference between routes matters. Findings from an oral tablet or topical cream cannot be transferred to an injection, and evidence about pigmentation cannot prove broad wellness claims.

What “compounded” changes

FDA says compounded drugs can meet an important need when an FDA-approved product cannot meet a patient's medical needs. FDA also states that compounded drugs are not FDA-approved, meaning the agency does not review their safety, effectiveness, or quality before marketing in the way it reviews an approved drug.

Oversight depends partly on the compounding setting. State boards of pharmacy generally carry day-to-day responsibility for state-licensed pharmacies that are not registered outsourcing facilities, while FDA inspects registered outsourcing facilities on a risk-based schedule. “Compounded” therefore does not identify one uniform regulatory or production system.

None of that determines whether a specific prescription is appropriate. It does mean the identity of the actual compounder should be available before purchase, not treated as an invisible fulfillment detail after checkout.

What the recall does not mean

• It is not a recall of every glutathione injection. The notice identifies one product, concentration, package size, pharmacy, lot, and expiration date.
• It does not connect every telehealth provider to the recalled product. We found no such connection in the public sources reviewed.
• It does not certify other lots as risk-free. A narrow recall defines the affected product; it is not a blanket quality guarantee for everything outside that scope.
• It does not answer the efficacy question. Product quality and clinical effectiveness are separate questions requiring different evidence.
• It does not make every advertised price comparable. Membership-only, introductory, and medication-inclusive prices need different labels.

Questions to ask before enrolling

• Which licensed pharmacy will dispense the prescription?
• Is the quoted figure medication-inclusive, or is it only a care membership?
• What quantity, concentration, and refill interval does the price cover?
• Is the displayed number introductory, ongoing, or dependent on prepayment?
• How will the provider communicate recalls or other safety notices?
• Can the provider identify the pharmacy and lot before the first dose is used?
• What is the cancellation or refund process if the clinician does not prescribe?